Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | IL6ST | P40189 | 5/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 13/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926817 | 1.00 | PIK3CD (0.56) | PIK3CDIL6STARSTAT3IDH1 | |
| SCHEMBL9926814 | 1.00 | PIK3CD (0.56) | PIK3CDIL6STARSTAT3IDH1 | |
| SCHEMBL21657352 | 0.81 | PIK3CD (0.42) | PIK3CDIL6ST | |
| SCHEMBL2033251 | 0.81 | PIK3CD (0.42) | PIK3CDIL6ST | |
| SCHEMBL10308941 | 0.80 | PIK3CD (0.42) | PIK3CDIL6STIDH1 | |
| SCHEMBL1717114 | 0.79 | PIK3CD (0.44) | PIK3CDIL6STARSTAT3IDH1 | |
| SCHEMBL12706216 | 0.79 | PIK3CD (0.41) | PIK3CDIL6ST | |
| SCHEMBL21657351 | 0.78 | PIK3CD (0.40) | PIK3CDIL6ST | |
| SCHEMBL10308833 | 0.77 | PIK3CD (0.55) | PIK3CDIL6STSTAT3IDH1 | |
| SCHEMBL18391318 | 0.77 | PIK3CD (0.55) | PIK3CDIL6STSTAT3IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464297-B1 | PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF | Dr Reddys Laboratories Ltd (IN) | 2023-10-25 | — | — | EP | disclosed |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-02 | — | — | US | disclosed |
| US-11091486-B2 | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof | ARRAY BIOPHARMA, INC (US) | 2021-08-17 | — | — | US | disclosed |
| US-11059799-B2 | Process for preparation of eribulin and intermediates thereof | DR. REDDY'S LABORATORIES LIMITED. (IN) | 2021-07-13 | — | — | US | disclosed |
| US-10966985-B2 | Macrocyclic compounds as ROS1 kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200392130-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
| US-10836776-B2 | Process for preparation of eribulin and intermediates thereof | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-11-17 | — | — | US | disclosed |
| US-20200216451-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | ARRAY BIOPHARMA, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20190276470-A1 | PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-09-12 | — | — | US | disclosed |
| US-20190076436-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-03-14 | — | — | US | disclosed |
| US-9643927-B1 | Process for the preparation of kinase inhibitors and intermediates thereof | AERIE PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170112842-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9624183-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150315165-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140309413-A1 | METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014164533-A1 | METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8093386-B2 | Thioaryl substituted inhibitors of zinc proteases and their use | BRACCO IMAGING S.P.A (IT) | 2012-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059799-B2 | Process for preparation of eribulin and intermediates thereof | ERLIN1, ERLIN2, MAN1B1 | PIK3CD 2826/4885IL6ST 2466/4885AR 2182/4885 |
| US-10836776-B2 | Process for preparation of eribulin and intermediates thereof | ERLIN1, ERLIN2, DHPS | PIK3CD 1977/4885IL6ST 2497/4885AR 2217/4885 |
| US-20200392130-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN3B, GRIN3A | PIK3CD 2131/4885IL6ST 333/4885AR 840/4885 |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | PIK3CD 201/4885IL6ST 3179/4885AR 1859/4885 |
| US-11091486-B2 | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof | DPYD, TYMP, UMPS | PIK3CD 2669/4885IL6ST 3225/4885AR 1810/4885 |
| US-10966985-B2 | Macrocyclic compounds as ROS1 kinase inhibitors | ROS1, MAP3K1, MAP3K19 | PIK3CD 368/4885IL6ST 1155/4885AR 1126/4885 |
| US-20150315165-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | CYP2B6, CYP2F1, CYP3A5 | PIK3CD 3266/4885IL6ST 508/4885AR 2940/4885 |
| US-20190276470-A1 | PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF | ERLIN1, ERLIN2, DHPS | PIK3CD 1977/4885IL6ST 2497/4885AR 2217/4885 |
| US-20140309413-A1 | METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS | NUDT1, PAPSS1, NT5C3B | PIK3CD 1822/4885IL6ST 3004/4885AR 3744/4885 |
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | GRIN2B, GRIN3B, GRIN3A | PIK3CD 2131/4885IL6ST 333/4885AR 840/4885 |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL12, RPL13A | PIK3CD 1374/4885IL6ST 981/4885AR 3691/4885 |
| US-20190076436-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ROS1, MAP3K1, MAP3K19 | PIK3CD 368/4885IL6ST 1155/4885AR 1126/4885 |
| US-20200216451-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | DPYD, TYMP, UMPS | PIK3CD 2669/4885IL6ST 3225/4885AR 1810/4885 |
| US-20170112842-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PIK3CD 624/4885IL6ST 791/4885AR 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.